Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sonic Innovations

This article was originally published in The Gray Sheet

Executive Summary

Hearing aid maker's initial public offering proceeds reach $53.9 mil. following the exercise of a 540,000-share overallotment option by underwriters Goldman Sachs, Deutsche Banc Alex. Brown and U.S. Bancorp Piper Jaffray. Completed May 9, the Salt Lake City firm's IPO included a total of 4.1 mil. shares at $14 each, including the overallotment shares (1"The Gray Sheet" May 8, p. 10)

You may also be interested in...



Sonic Innovations, Inc.

Hearing aid maker goes public May 1 via initial offering of 3.6 mil. shares of common stock at $14 per share to raise $50 mil. Larger than an initially anticipated offering of up to $46 mil., the offering will help fund commercialization of the firm's Conforma digital hearing aid (1"The Gray Sheet" March 20, p. 17). The device debuted March 16. The Salt Lake City-based company also will use a portion of the proceeds for further R&D and debt repayment. Sonic Innovation shares will trade on the Nasdaq exchange under the symbol "SNCI." Underwriters Goldman Sachs, Deutsche Banc Alex. Brown and U.S. Bancorp Piper Jaffray have a 30-day overallotment option to purchase up to an additional 540,000 shares

Will MDR Delays Create Roadblocks For Companion Diagnostics Regulation?

Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed is there a risk of delays to these products being able to demonstrate compliance?

India Rare Disease Policy Proposes Crowdfunding But Patients Feel Let Down

Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.

UsernamePublicRestriction

Register

MT013416

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel